SUPPLEMENTARY MATERIAL

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Lauren S. Gollahon, Yunseong Jeong, Velvetlee Finckbone, Kyungwoo Lee and Jong-Sang Park

Suppl. Fig. (1). Results of HCC1419 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. A) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. B) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.
Suppl. Fig. (2). Results of MCF7 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. A) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. B) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.
Suppl. Fig. (3). Results of MDA-MB-468 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. A) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. B) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.
Suppl. Fig. (4). Results of SKBR3 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. A) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. B) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.
Suppl. Fig. (5). Results of HME cell viability and drug cytotoxicity during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 (7 days) or Taxol™ (24 h). Fresh medium was added on day 3 LC50. A) Cell viability during LC50 was determined by Trypan Blue exclusion performed simultaneously with cell counts. B) Cell viability during Recovery was determined by Trypan Blue exclusion performed simultaneously with cell counts. C, D) Cytotoxicity of NI-07 and Taxol™ on HME cells during LC50 and Recovery, respectively. The cytotoxicity of NI-07 and Taxol™ was determined by XTT analysis.
Suppl. Fig. (6). Results of fibroblast cell viability and drug cytotoxicity during treatment with NI-07. CCDsk cells were plated and 24 - 48 h later, treated with either NI-07 (7 days) or Taxol™ (24 h). Fresh medium was added on day 3 LC50. A) Cell viability during LC50 was determined by Trypan Blue exclusion performed simultaneously with cell counts. B) Cell viability during Recovery was determined by Trypan Blue exclusion performed simultaneously with cell counts. C, D) Cytotoxicity of NI-07 and Taxol™ on HME cells during LC50 and Recovery, respectively. The cytotoxicity of NI-07 and Taxol™ was determined by XTT analysis.